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Abstract
Selenium is a micronutrient that had been suggested to reduce the risk of 
cancer. Hepatocellular carcinoma (HCC), a prevalent disease and one of the most 
lethal cancers in the world, awaits new alternative treatment strategies to improve 
patients’ survival. As an essential trace element, selenium has been studied for its 
anticancer properties in both oxidative stress and inflammatory-related mecha-
nisms that may contribute to HCC growth and metastasis. In recent decades, 
increasing studies have investigated the potential role of selenium in liver cancer 
involving several major cancer-associated signaling pathways, metabolic pathways, 
and antioxidant defense systems both in vitro and in preclinical models. It was also 
observed that there was an increase in the trend of development of novel selenium 
nanoparticles and selenium-containing inhibitors aiming to improve the therapeu-
tic efficacy and relative potency of selenium. However, controversies remain with 
whether a relationship exists between serum selenium level and HCC risk. This 
chapter aims to summarize the multi-target and multi-pathway in vitro and in vivo 
pharmacological effects of selenium in HCC, to provide a more comprehensive view 
and to highlight the recently discovered molecular mechanisms We hope this chap-
ter could outline the correlation of selenium level and the risk of HCC in patients 
and discuss the clinical application of selenium in HCC prevention and treatment.
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1. Introduction
Selenium (Se) is a naturally occurring essential micronutrient which had been 
received considerable attention in medicine and biology. As an essential component 
for mammalian cellular function, for the synthesis of several antioxidant enzymes, 
such as glutathione peroxidase, and for the synthesis of selenoproteins, selenium 
not only plays a vital role in balancing the redox environment in the body, but also 
is related to the prevention of diseases related to free radical damage, including 
infectious diseases, cancer, and cardiovascular diseases [1, 2]. The relationship 
between selenium and health has been the focus of medical community [3]. While 
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early observational studies have shown that the trace element selenium in the envi-
ronment is closely related to the occurrence and development of tumors [3]. The 
incidence of cancer in patients with selenium deficiency is significantly increased, 
and the amount of selenium in the body is negatively correlated with cancer [4]. 
Furthermore, while some studies suggested selenium supplementation reduces the 
risk of cancer, some methodologically sound trials suggested selenium supplemen-
tation does not reduce the risk of cancer and may even increase it for some types, 
including advanced prostate cancer and skin cancer [5, 6]. An increased risk of 
diabetes has also been reported [7]. The relationship between selenium and cancer 
has been one of the most heated debates in human health over the past few decades. 
Moreover, the potential effect of selenium in the prevention and treatment of HCC 
is worthy of further investigation.
Primary liver cancer (PLC) is one of the most prevalent malignancies world-
wide, and its incidence ranks fourth among all malignancies in China [8, 9]. The 
overall prognosis for patients with PLC is unsatisfactory with a 5-year survival rate 
of about 18%, and its mortality rate ranks the third in tumor-related death [10]. 
HCC is the most prevalent pathological type of PLC, accounting for about 85–90% 
of all PLCs [11]. Among all HCC patients, approximately 70–90% of them pre-
sented with a history of chronic liver diseases and cirrhosis [12]. While the primary 
risk factors for developing cirrhosis include chronic hepatitis B virus (HBV), 
hepatitis C virus (HCV), alcoholic liver disease, and nonalcoholic steatohepatitis 
(NASH), some other risk factors for HCC include uptake of aflatoxin-contaminated 
food, diabetes, obesity, certain genetic diseases such as hemochromatosis and some 
metabolic disorders [9, 11, 13]. Also, geographical factors have a direct impact 
on the various etiological features of HCC patients and make HCC an extremely 
complex condition associated with poor prognosis.
Epidemiology studies have found that the geographical factors and specific 
environmental exposures may be associated with HCC [14]. Inconsistent with 
the world’s selenium distribution patterns, previous epidemiological studies have 
highlighted the particular relevance of selenium-associated cancer risk to the 
region of low selenium distribution, such as Asia or Africa [5, 15]. Some earlier 
surveying studies found that low environmental selenium is associated with certain 
cancers in the digestive system, and selenium supplementation may provide some 
cancer prevention effect [16]. However, the results had been inconsistent through-
out various studies. Previous intervention trials in regions with low environmental 
selenium have shown a beneficial effect of selenium supplementation for cancer 
patients, while in most parts of North America, where there is sufficient envi-
ronmental selenium, supplemental intake of selenium appears to be unrelated to 
chemoprevention [5, 17].
In Qidong, Jiangsu province, China, there is a high incidence of HCC and low 
environmental selenium level [18]. Various studies carried out in the region unrav-
eled the negative correlation of HCC mortality with serum selenium level and 
environmental selenium level [19, 20]. However, in other areas in the world with 
low environmental selenium level, such correlation was not observed, suggesting 
that selenium deficiency may not be the sole cause of liver cancer and other factors, 
such as environmental carcinogens, the of heavy industry, chemical industry, etc. 
may collaboratively contribute to the high incidence of HCC [4].
Since the 1970s, continuous efforts had been made on studying the potential 
anti-cancer effect of selenium supplementation. Decrease of serum selenium 
level has also been observed in patients with chronic liver diseases. Mechanically, 
selenium plays a vital role in maintaining healthy liver function and synthesis of 
essential liver enzymes [21, 22]. Selenium protects the liver mainly in the following 
aspects: (1) reduces the damage of toxic substances in the environment to the liver; 
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(2) protects the integrity of the liver cell membrane by scavenging free radicals 
and preventing lipid peroxides through glutathione peroxidase; (3) accelerates 
the catabolism of ethanol, protecting the liver from alcoholic damage; and (4) 
stimulates both the humoral and cellular immunity and enhances immune function 
against hepatitis virus. The present article reviews the roles of selenium in HCC.
2. The preventive role of selenium in HCC tumorigenesis
One of the most recognized roles of selenium is to prevent cancer. Since 
the 1970s, the tumorigenesis prevention role of selenium has also been studied 
in various chemical carcinogen-induced HCC models; for example, selenium 
can significantly suppress liver cancer carcinogenesis induced by aflatoxin B1, 
dimethyl azobenzene, or acetylamino. Consumption of food with Aflatoxin B1 
(AFB1) contamination is one of the leading causes of liver cancer. In 1985, Milks, 
et al. investigated the effect of selenium on aflatoxin hepatocarcinogenesis in the 
rat model and found that oral supplementation of selenium can dose- and time-
dependently reduces aflatoxin B1-induced γ-GT variant hepatocyte foci and tumor 
nodules in rat liver [23]. Similarly, another animal study by Lei et al. in 1990 also 
found that selenium supplementation had an inhibitory effect on the initiation and 
promotion stages of AFB1-induced preneoplastic foci and nodules in HCC model 
without evidence of toxicity [24]. Further study showed that oral supplementation 
of selenium could dose- and time-dependently reduces aflatoxin B1-induced γ-GT 
variant hepatocyte foci and tumor nodules in animal models. Shi et al. demon-
strated that selenium could reduce the amount of AFB1-DNA binding and effec-
tively inhibit AFB1-induced DNA damage [25]. The main reason may be that AFB1 
binds to glutathione (GSH) under the catalysis of the glutathione-S-converting 
enzyme (GSTS) and is excreted in a non-toxic form, thereby reducing the forma-
tion of AFB1-DNA compounds.
Diethylnitrosamine (DENA)-induced and phenobarbital (PB)-promoted HCC 
model is one of the most popular chemically induced HCC models used [26]. 
Thirunavukkarasu et al. conducted various studies investigating the chemopreven-
tive properties and biochemical mechanisms of sodium selenite supplementation in 
the DENA-initiated and PB-promoted HCC rodent model with four parts per mil-
lion (p.p.m.) of sodium selenite in drinking water for 14 weeks. Selenium supple-
mentation elevates malate dehydrogenase level, a vital enzyme of the citric acid 
cycle [27]; increases superoxide dismutase (SOD and catalase (CAT) levels, two key 
antioxidant enzymes [28, 29]; decreases glutathione transferase (GST) level [30]; 
decreases alanine transaminase (AST), aspartate transaminase (ALT), and lactate 
dehydrogenase (LDH) elevations [31]; suppresses the elevated glycoprotein levels 
of glycoproteins such as globulin and hexosamine [32]; elevates ATPase enzymatic 
level and alters serum mineral levels [33, 34]; as well as increases vitamins C and E 
[35] in the DENA-initiated and PB-promoted HCC rodent model.
A more recent study by Liu et al. investigated the effects of selenium-enriched 
malt (SEM) on hepatocarcinogenesis, paraneoplastic syndrome, the hormones 
regulating blood glucose, vascular endothelial growth factor (VEGF), and several 
relevant angiogenic cytokines in DENA-induced HCC rat model [36–38]. The 
results showed that SEM decreased several liver enzyme levels, including alanine 
aminotransferase (ALT), alkaline phosphatase (ALP), as well as gamma-glutam-
yltranspeptidase (GGT); increased glucose levels and reduced hypoglycemia; 
and inhibited the angiogenesis by downregulating the expression of VEGF and 
interacted with tumor necrosis factor-alpha (TNF-α) and insulin-like growth factor 
II (IGF-II), and nitric oxide (NO). These results suggested that SEM may delay the 
Importance of Selenium in the Environment and Human Health
4
development of hepatocarcinoma in DENA-induced HCC rat model and partially by 
the inhibition of angiogenesis [38].
Other preclinical animal models had also been used to study the effect of 
selenium in liver cancer. Nine or thirteen weeks of sodium selenite (6 p.p.m) 
supplementation in drinking water prevented the azo dye (3′-MeDAB) hepatocar-
cinogenesis in male Sprague-Dawley rats [39, 40]. Supplementation with sodium 
selenite or selenomethionine reduces the focal volume and lower GST level in 
2-acetylaminofluorene (2-AAF)-induced hepatocarcinogenesis rat model [41–43]. 
Sodium selenite suppressed the BOP-induced HCC in Syrian hamsters and induced 
apoptosis and caspase-3 level [44]. In the transgenic mice model, selenium supple-
mentation also demonstrates anti-hepatocarcinogenesis effect. For example, in CBA 
mice, prenatal administration of selenium significantly decreased the spontaneous 
liver tumorigenesis [45]; in TGF-α/c-Myc transgenic mice, dietary selenium supple-
mentation inhibited hepatocarcinogenesis, promoted apoptosis, and suppressed 
cell proliferation [46]; in Mdr2 knock-out mice, selenomethionine suppressed the 
development of HCC by regulating various genes involved in inflammation and 
oxidative stress [47]. In HCC xenograft, selenium-enriched green tea extracts also 
showed a suppressive effect in human hepatoma HepG2 cell mice xenograft model 
[48]. These results suggested that selenium holds a significant promising role as a 
potential anti-cancer agent in vivo in various liver cancer models.
3.  Anti-cancer effect of selenium and the potential underlying 
mechanism
Since the 1970s, the potential anti-tumor effects of selenium have attracted 
considerable research attention. In vitro studies have shown proliferation inhibi-
tory role of selenium in liver cancer, colon cancer, gastric cancer, etc. [49, 50]. 
Various in vivo and in vitro studies have revealed its promising anti-tumor role 
breast cancer, lung cancer, colorectal cancer, etc. [51, 52]. These results suggest the 
broad-spectrum anti-cancer effect of selenium. In recent decades, increasing stud-
ies have investigated the potential role of selenium in liver cancer, involving several 
major cancer-associated signaling pathways, metabolic pathways, and transcrip-
tion factors.
4. Anti-proliferative and apoptosis induction role of selenium in HCC
One of the earlier studies by Baker et al. in the 1990s on human hepatoma Hep3B 
cell line showed that selenium supplementation restores glutathione peroxidase 
mRNA expression in selenium-deprived cell culture [53]. Hill et al. investigated in 
human liver cancer HepG2 cell line showed that in selenium-deprived HepG2 cells, 
selenoprotein P release decreased to 10% [54]. Further, various studies consis-
tently reported apoptosis induction effect of selenite in human hepatoma cells 
HepG2 cells, potentially by inducing the release of lactate dehydrogenase (LDH) 
and decreasing glutathione (GSH) production [55–57]. Another study reported 
that selenite-induced apoptosis in HepG2 cells was mediated by reactive oxygen 
species (ROS) that activated JNK to regulate apoptosis [58]. A more recent study 
on selenium nanoparticle surface decorated with galangin can induce apoptosis 
through p38 and AKT signaling pathway in HepG2 cells [59]. Similarly, selenium 
nanoparticles synthesized with extract of hawthorn fruit also induced apoptosis in 
HepG2 cells [60]. Various mechanisms may be involved in the apoptosis induction 
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role of selenium and selenium-containing inhibitors for HCC. Tagaram et al. 
reported a selenium-containing MAPK and PI3 kinase inhibitor, the Se, Se′-1,4-
phenylenebis(1,2-ethanediyl) bisisoselenourea (PBISe), possesses anti-proliferative 
and pro-apoptotic ability in HCC cell lines in vitro and in in vivo in a spontaneous 
murine HCC model [39]. PBISe promoted apoptosis by inhibiting PI3K, MAPK, and 
STAT3 signaling in vitro and with significant reduce tumor sizes in vivo (p < 0.007) 
with a significant reduction in tumor survival marker PCNA and angiogenesis 
markers Vegf-A, Vegf-R3, and CD34 [39]. These results demonstrate the chemother-
apeutic effects of selenium by inhibiting tumor proliferation and inducing tumor 
apoptosis for HCC treatment.
5. Anti-oxidation effect of selenium in HCC
Oxidative stress is characterized by the excessive production of oxidants or 
ROS and insufficient elimination by protective antioxidants [40]. This persistent 
imbalance may lead to somatic mutations and neoplastic transformation [40]. In 
cancer, ROS is commonly found elevated and is a key constituent to cancer survival 
[61, 62]. Most of the effects of dietary selenium on oxidation are attributable to 
the insertion of this element to selenoproteins, mostly its cofactor glutathione 
peroxidase. In the active oxidative metabolism, selenium-dependent glutathione 
peroxidase acts with tripeptide glutathione (GSH) and competes for the catalyza-
tion for hydrogen peroxide as a substrate, scavenging reactive oxygen species (ROS) 
and lipid peroxide (LPO) [63]. In 2007, a study by Katzenellenbogen et al. investi-
gated the effect of selenomethionine on oxidative stress and inflammation or lipid 
metabolism with cDNA microarrays in HCC development in Mdr2 knockout mice 
model [47]. The results showed that selenomethionine alters the expression of com-
monly upregulated genes found in response to inflammation, oxidative stress, and 
cancer [47]. Further, the inhibitory effect on gene expression of selenomethionine 
is positively correlated with its role to reduce the incidence of large tumors [47]. 
These results provide a theoretical basis for the anticancer mechanism of selenium.
6. Anti-metastasis effect of selenium in HCC
HCC is characterized by its invasive and metastatic potential [64]. In liver can-
cer, it has been suggested that SBP1, a Se-containing protein, and its primary func-
tion is Se transport, plays a role in metastasis and if found to be highly expressed in 
healthy liver tissue but was nearly non-detectable in highly metastatic liver cancer 
cell lines [65]. Epithelial-mesenchymal transition (EMT) is a process that plays a 
vital role in HCC metastasis cascade and had been suggested to be closely related to 
the initiation of HIF-1α [64]. SBP-1 is a downstream target of HIF-1α and has been 
found that loss of SBP1 promoted liver cancer cell migration and increased GPX1 
activity, which further suppresses in hydrogen peroxide and other reactive oxygen 
species, leading to the inhibition of HIF-1α [64]. Recently study by Gao et al. 
identified 186 differentially expressed genes among control and SBP1 expressing 
HCC cells [66]. Further investigation showed C-X-C motif chemokine receptor 4 
(CXCR4) expression was inhibited by SBP1 and is closely related to the migration 
and invasion ability of HCC cells through activation of AKT signaling [66]. These 
results suggested the potential application of selenium in liver cancer metastasis 
prevention and treatment; however, more data from in vitro and in vivo are war-
ranted to solidify effect and mechanism of action.
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7. Epidemiological investigations and clinical trials
Many studies have shown that the level of blood selenium in patients with 
chronic liver disease is reduced, and it can be corrected by selenium supplementa-
tion [67–69]. Selenium supplementation can inhibit the lipid peroxidation of 
immune cells in patients with liver diseases, regulate cellular immune function, and 
alleviate immunopathological damage. In the treatment of patients with chronic 
hepatitis, in the anti-viral, immune-modulating, and liver-protecting treatment, 
it is beneficial to correct the blood selenium level of hepatitis patients by detect-
ing and conditioning so that lipid oxidation and liver repair could be resisted [12]. 
Selenium and selenium supplementation for the treatment of liver disease should 
attract the attention of the medical community. However, controversies remain 
with whether a relationship exists between serum selenium level and HCC risk.
Some pioneering studies performed in China in the 1990s showed that plasma 
selenium level is negatively correlated with the occurrence of HCC in areas with 
low environmental selenium level [19, 20]. A preliminary report by Yu et al. in 
1991 of two intervention trials in high-risk populations of PLC with selenium 
supplementation in Qidong, Jiangsu province, China, showed that among individu-
als with a family history of PLC, oral supplementation of 200 mg selenium in the 
form of selenized yeast (Se-yeast) daily for 4 and 2 years, respectively, showed 
significant reduction in PLC incidence compared with placebo [19]. Another study 
by Yu et al. in 1997 of an interventional trial among 130,471 individuals living in 
Qidong Country showed that a reduction PLC incidence by 35.1% in selenite table 
salt supplemented group vs. the non-supplemented group after an 8-year follow-up. 
Consistently, an epidemiological study in Taiwan by Yu et al. involving a cohort of 
7342 chronic carriers of hepatitis B and C virus male with an average of 5.3 years 
of follow-up showed an inverse association between plasma selenium levels and 
the risk of HCC among men with chronic hepatitis virus infection [70]. Another 
study in Korea by Kim et al. in 2012 also reported an apparent correlation between 
low plasma selenium level and incidence of HCC in Korean hepatoma patients [71]. 
However, no relationship was observed between plasma selenium concentration 
and incidence of HCC in a study with Japanese hepatoma patients [72]. In 2016, a 
systemic review meta-analysis involving 9 trials and a total of 1433 subjects sup-
ported an inverse correlation between Se level and the risk of HCC, and lowered 
Se level had a relationship with HCC with a remarkable heterogeneity (I2 = 74.3%, 
P < 0.001) [4]. However, epidemiological investigations and biological studies 
should be further conducted to demonstrate and verify whether selenium supple-
ments are beneficial for the prevention and treatment of HCC and to elucidate its 
exact mechanism of action.
8. Discussion and conclusion
Over decades, an increase in the trend of development of novel selenium 
nanoparticles and selenium-containing inhibitors aims to improve the therapeutic 
efficacy and relative potency of selenium. Experimental studies with animal tumor 
models and epidemiological studies of human tumors have revealed that selenium is 
one of the factors affecting the risk of cancer. The huge number of publications has 
suggested the potential role of selenium and redox-active selenium compounds as 
inhibitors and therapeutic agents for liver cancer. However, the studies are difficult 
to compare among different selenium compounds due to a high degree of variations 
on the effective dosage anti-proliferation due to the difference in the ex vivo culture 
condition.
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Further, although some epidemiology studies have supported the hypothesis 
that selenium supplementation can reduce the risk of cancer, inconsistent results 
have also been reported. Another important aspect of being considered for the use 
of selenium-containing compounds in anticancer is as a chemical protective agent 
against toxic side effects of anticancer drugs. Selenium has also been reported to 
have a protective effect against cisplatin-induced nephrotoxicity without affecting 
its anti-tumor activity in rodent model [73]. Further trials are needed to confirm 
the selenium supplementation for liver cancer in terms of its effect on prognosis as 
well as potential toxic effect.
This chapter summarizes the pharmacological effects of selenium in HCC in 
vitro and in vivo, and to highlight the recently discovered molecular mechanisms, 
to outline the correlation of selenium level and the risk of HCC in patients, and to 
discuss the clinical application of selenium in HCC prevention and treatment. In 
conclusion, the preclinical studies presented in this chapter summarized the prom-
ise of selenium as a potential anti-cancer agent and presented the chemo-preventive 
role in HCC. Although substantial evidence for the anti-cancer effect of selenium is 
discussed, further studies are warranted.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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